IMNM
Price:
$13.54
Market Cap:
$813.14M
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2020-10-02
Stock Exchange
NASDAQ
Ticker
IMNM
According to Immunome, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.80. This represents a change of -39.99% compared to the average of -3.00 of the last 4 quarters.
The mean historical PE Ratio of Immunome, Inc. over the last ten years is -4.26. The current -1.80 PE Ratio has changed 4.12% with respect to the historical average. Over the past ten years (40 quarters), IMNM's PE Ratio was at its highest in in the March 2024 quarter at -0.44. The PE Ratio was at its lowest in in the March 2021 quarter at -23.12.
Average
-4.26
Median
-4.05
Minimum
-7.53
Maximum
-0.71
Discovering the peaks and valleys of Immunome, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 218.88%
Maximum Annual PE Ratio = -0.71
Minimum Annual Increase = -88.31%
Minimum Annual PE Ratio = -7.53
Year | PE Ratio | Change |
---|---|---|
2023 | -1.99 | 178.27% |
2022 | -0.71 | -88.31% |
2021 | -6.11 | 218.88% |
2020 | -1.92 | -73.83% |
2019 | -7.32 | -2.69% |
The current PE Ratio of Immunome, Inc. (IMNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.94
5-year avg
-3.61
10-year avg
-4.26
Immunome, Inc.’s PE Ratio is greater than Anebulo Pharmaceuticals, Inc. (-4.99), greater than Adagene Inc. (-2.86), greater than Acrivon Therapeutics, Inc. Common Stock (-4.23), greater than AnaptysBio, Inc. (-5.77), greater than Mineralys Therapeutics, Inc. (-4.63), greater than Molecular Partners AG (-2.67), greater than MediciNova, Inc. (-12.61), greater than Champions Oncology, Inc. (-7.94), greater than Cyteir Therapeutics, Inc. (-3.52), less than Aerovate Therapeutics, Inc. (-0.62), greater than Rezolute, Inc. (-3.80), less than AN2 Therapeutics, Inc. (-0.47), less than Gain Therapeutics, Inc. (-0.93), less than TFF Pharmaceuticals, Inc. (-0.34), greater than aTyr Pharma, Inc. (-2.33), less than IN8bio, Inc. (-0.43), greater than Lantern Pharma Inc. (-2.07), less than Ikena Oncology, Inc. (-1.22), greater than Celcuity Inc. (-7.01),
Company | PE Ratio | Market cap |
---|---|---|
-4.99 | $46.68M | |
-2.86 | $115.55M | |
-4.23 | $250.26M | |
-5.77 | $1.08B | |
-4.63 | $558.43M | |
-2.67 | $182.90M | |
-12.61 | $103.00M | |
-7.94 | $57.77M | |
-3.52 | $108.71M | |
-0.62 | $54.85M | |
-3.80 | $240.80M | |
-0.47 | $30.44M | |
-0.93 | $26.81M | |
-0.34 | $6.20M | |
-2.33 | $131.12M | |
-0.43 | $14.22M | |
-2.07 | $36.82M | |
-1.22 | $81.56M | |
-7.01 | $557.67M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunome, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immunome, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Immunome, Inc.'s PE Ratio?
How is the PE Ratio calculated for Immunome, Inc. (IMNM)?
What is the highest PE Ratio for Immunome, Inc. (IMNM)?
What is the 3-year average PE Ratio for Immunome, Inc. (IMNM)?
What is the 5-year average PE Ratio for Immunome, Inc. (IMNM)?
How does the current PE Ratio for Immunome, Inc. (IMNM) compare to its historical average?